I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Oberic, L.
319
results:
english X
Search for persons
X
Format
Online (319)
Mediatypes
Articles (Online) (96)
OpenAccess-fulltext (223)
Sorted by: Relevance
Sorted by: Year
?
1
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG ..:
Sarkozy, C.
;
Thieblemont, C.
;
Oberic, L.
...
Hematological Oncology. 41 (2023) S2 - p. 151-152 , 2023
Link:
https://doi.org/10.1002/..
?
2
Tafasitamab lenalidomide in relapsed/refractory large B‐cel..:
Paillassa, J.
;
Degoutte, C.
;
Oberic, L.
...
Hematological Oncology. 41 (2023) S2 - p. 591-592 , 2023
Link:
https://doi.org/10.1002/..
?
3
Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T..:
Marouf, A.
;
Chaubard, S.
;
Michot, J.
...
Hematological Oncology. 41 (2023) S2 - p. 502-503 , 2023
Link:
https://doi.org/10.1002/..
?
4
Molecular and clinical diversity in primary central nervous..:
Hernández-Verdin, I.
;
Kirasic, E.
;
Wienand, K.
...
Annals of Oncology. 34 (2023) 2 - p. 186-199 , 2023
Link:
https://doi.org/10.1016/..
?
5
Brigatinib in patients with ALK‐positive anaplastic large c..:
Veleanu, L.
;
Tesson, B.
;
Lamant, L.
...
Hematological Oncology. 41 (2023) S2 - p. 505-506 , 2023
Link:
https://doi.org/10.1002/..
?
6
EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OU..:
Delfau‐Larue, M.
;
Viailly, P.
;
Cartron, G.
...
Hematological Oncology. 41 (2023) S2 - p. 179-181 , 2023
Link:
https://doi.org/10.1002/..
?
7
AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐..:
Houot, R.
;
Bachy, E.
;
Cartron, G.
...
Hematological Oncology. 41 (2023) S2 - p. 147-148 , 2023
Link:
https://doi.org/10.1002/..
?
8
LONG‐TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLI..:
Camus, V.
;
Belot, Aurél.
;
Oberic, L.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
9
HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA ST..:
Cheminant, M.
;
Burroni, B.
;
Le Bris, Y.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
10
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACT..:
Wang, M.
;
Rule, S.
;
Zinzani, P. L.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
11
REAL WORLD OUTCOME IN MANTLE CELL LYMPHOMA: A FRENCH RETROS..:
Branco, B
;
Bories, P
;
Ysebaert, L
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
12
Efficacy of dupilumab in eosinophilic dermatosis of haemato..:
Sibaud, V.
;
Brun, A.
;
Meyer, N.
...
Journal of the European Academy of Dermatology and Venereology. 36 (2021) 3 - p. , 2021
Link:
https://doi.org/10.1111/..
?
13
Orbital exenteration and conjunctival melanoma: a 14-year s..:
Martel, A.
;
Oberic, A.
;
Moulin, A.
...
Eye. 34 (2020) 10 - p. 1897-1902 , 2020
Link:
https://doi.org/10.1038/..
?
14
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRA..:
Le Gouill, S.
;
Beldi‐Ferchiou, A.
;
Cacheux, V.
...
Hematological Oncology. 37 (2019) S2 - p. 44-45 , 2019
Link:
https://doi.org/10.1002/..
?
15
IBRUTINIB ABOVE 79 YEARS OLD FOR CHRONIC LYMPHOCYTIC LEUKEM..:
Calleja, A.
;
Branco, B.
;
Teste, A.
...
Hematological Oncology. 37 (2019) S2 - p. 384-384 , 2019
Link:
https://doi.org/10.1002/..
1-15